Cara Therapeutics, Inc. (NASDAQ:CARA – Free Report) – Equities researchers at HC Wainwright lifted their Q2 2024 earnings per share estimates for shares of Cara Therapeutics in a note issued to investors on Wednesday, May 15th. HC Wainwright analyst O. Livnat now expects that the biopharmaceutical company will post earnings per share of ($0.22) for […]
– Oral difelikefalin as adjunct to topical corticosteroids did not demonstrate meaningful clinical benefit compared to TCS alone; As a result, Cara will discontinue its clinical program in pruritus.
– Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025 – – Key data readouts for all.